Aspirin and urinary 11-dehydrothromboxane B 2 in African American stroke patients

Askiel Bruno, Joseph P. McConnell, Harry H. Mansbach, Stanley N. Cohen, Gretchen E. Tietjen, Nils U. Bang

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background and Purpose-The aim of the study was to evaluate the relationship between daily aspirin use and urinary excretion of a stable thromboxane metabolite, 11-dehydrothromboxane B 2 (11-DTB2), in African American stroke patients. Methods-Subjects were a subgroup of those screened for the African American Antiplatelet Stroke Prevention Study. Subjects were within 4 months of noncardioembolic ischemic stroke and were not being treated with anticoagulants. Antithrombotic therapy at the time of urine collection varied according to the practice patterns of various attending physicians who treated the patients during their acute strokes. 11-DTB2 was measured by enzyme immunoassay in random urine samples 1 to 4 months after the stroke. Results-Eighty-seven of 92 patients enrolled were able to give a urine sample at the time of enrollment. There were 51 men and 36 women aged 36 to 87 (mean 62) years. On the basis of antithrombotic treatment before the sample collection, we divided patients into 4 groups: (1) 16 patients treated with no aspirin (no antithrombotic drugs [n=4] or ticlopidine [n=12]), (2) 21 patients treated with 81 to 325 mg aspirin per day (81 mg/d [n=2], 325 mg/d [n= 19]), (3) 20 patients treated with 650 mg aspirin per day, and (4) 30 patients treated with 975 to 1300 mg aspirin per day (975 mg/d [n=2] and 1300 mg/d [n=28]). In patients taking daily aspirin at any dose, the median urinary 11-DTB2 was 783 pg/mg creatinine compared with 1386 pg/mg creatinine in patients not taking daily aspirin (P=0.01 by Wilcoxon rank sum test). In multivariate regression analysis, aspirin use remained significantly associated with lower urinary 11-DTB2 (P=0.008). There was no dose-response effect between the 3 aspirin dose groups and urinary 11-DTB2 (P=0.70). Conclusions-In African American stroke patients, aspirin use is associated with significantly lower urinary 11-DTB2 independent of other vascular factors, and there does not appear to be a dose-response effect for aspirin doses of 325 to 1300 mg daily. The clinical significance of these finding remains to be determined.

Original languageEnglish (US)
Pages (from-to)57-60
Number of pages4
JournalStroke
Volume33
Issue number1
DOIs
StatePublished - Jan 21 2002
Externally publishedYes

Fingerprint

African Americans
Aspirin
Stroke
Nonparametric Statistics
Creatinine
Urine
Ticlopidine
Urine Specimen Collection
Thromboxanes
Immunoenzyme Techniques
Anticoagulants
Multivariate Analysis
Regression Analysis
Physicians
Therapeutics

Keywords

  • Aspirin
  • Cerebral infarction
  • Platelets
  • Thrombosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Bruno, A., McConnell, J. P., Mansbach, H. H., Cohen, S. N., Tietjen, G. E., & Bang, N. U. (2002). Aspirin and urinary 11-dehydrothromboxane B 2 in African American stroke patients Stroke, 33(1), 57-60. https://doi.org/10.1161/hs0102.102010

Aspirin and urinary 11-dehydrothromboxane B 2 in African American stroke patients . / Bruno, Askiel; McConnell, Joseph P.; Mansbach, Harry H.; Cohen, Stanley N.; Tietjen, Gretchen E.; Bang, Nils U.

In: Stroke, Vol. 33, No. 1, 21.01.2002, p. 57-60.

Research output: Contribution to journalArticle

Bruno, A, McConnell, JP, Mansbach, HH, Cohen, SN, Tietjen, GE & Bang, NU 2002, ' Aspirin and urinary 11-dehydrothromboxane B 2 in African American stroke patients ', Stroke, vol. 33, no. 1, pp. 57-60. https://doi.org/10.1161/hs0102.102010
Bruno, Askiel ; McConnell, Joseph P. ; Mansbach, Harry H. ; Cohen, Stanley N. ; Tietjen, Gretchen E. ; Bang, Nils U. / Aspirin and urinary 11-dehydrothromboxane B 2 in African American stroke patients In: Stroke. 2002 ; Vol. 33, No. 1. pp. 57-60.
@article{5fd1c5f5774a4f089d672613ef57a96a,
title = "Aspirin and urinary 11-dehydrothromboxane B 2 in African American stroke patients",
abstract = "Background and Purpose-The aim of the study was to evaluate the relationship between daily aspirin use and urinary excretion of a stable thromboxane metabolite, 11-dehydrothromboxane B 2 (11-DTB2), in African American stroke patients. Methods-Subjects were a subgroup of those screened for the African American Antiplatelet Stroke Prevention Study. Subjects were within 4 months of noncardioembolic ischemic stroke and were not being treated with anticoagulants. Antithrombotic therapy at the time of urine collection varied according to the practice patterns of various attending physicians who treated the patients during their acute strokes. 11-DTB2 was measured by enzyme immunoassay in random urine samples 1 to 4 months after the stroke. Results-Eighty-seven of 92 patients enrolled were able to give a urine sample at the time of enrollment. There were 51 men and 36 women aged 36 to 87 (mean 62) years. On the basis of antithrombotic treatment before the sample collection, we divided patients into 4 groups: (1) 16 patients treated with no aspirin (no antithrombotic drugs [n=4] or ticlopidine [n=12]), (2) 21 patients treated with 81 to 325 mg aspirin per day (81 mg/d [n=2], 325 mg/d [n= 19]), (3) 20 patients treated with 650 mg aspirin per day, and (4) 30 patients treated with 975 to 1300 mg aspirin per day (975 mg/d [n=2] and 1300 mg/d [n=28]). In patients taking daily aspirin at any dose, the median urinary 11-DTB2 was 783 pg/mg creatinine compared with 1386 pg/mg creatinine in patients not taking daily aspirin (P=0.01 by Wilcoxon rank sum test). In multivariate regression analysis, aspirin use remained significantly associated with lower urinary 11-DTB2 (P=0.008). There was no dose-response effect between the 3 aspirin dose groups and urinary 11-DTB2 (P=0.70). Conclusions-In African American stroke patients, aspirin use is associated with significantly lower urinary 11-DTB2 independent of other vascular factors, and there does not appear to be a dose-response effect for aspirin doses of 325 to 1300 mg daily. The clinical significance of these finding remains to be determined.",
keywords = "Aspirin, Cerebral infarction, Platelets, Thrombosis",
author = "Askiel Bruno and McConnell, {Joseph P.} and Mansbach, {Harry H.} and Cohen, {Stanley N.} and Tietjen, {Gretchen E.} and Bang, {Nils U.}",
year = "2002",
month = "1",
day = "21",
doi = "10.1161/hs0102.102010",
language = "English (US)",
volume = "33",
pages = "57--60",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Aspirin and urinary 11-dehydrothromboxane B 2 in African American stroke patients

AU - Bruno, Askiel

AU - McConnell, Joseph P.

AU - Mansbach, Harry H.

AU - Cohen, Stanley N.

AU - Tietjen, Gretchen E.

AU - Bang, Nils U.

PY - 2002/1/21

Y1 - 2002/1/21

N2 - Background and Purpose-The aim of the study was to evaluate the relationship between daily aspirin use and urinary excretion of a stable thromboxane metabolite, 11-dehydrothromboxane B 2 (11-DTB2), in African American stroke patients. Methods-Subjects were a subgroup of those screened for the African American Antiplatelet Stroke Prevention Study. Subjects were within 4 months of noncardioembolic ischemic stroke and were not being treated with anticoagulants. Antithrombotic therapy at the time of urine collection varied according to the practice patterns of various attending physicians who treated the patients during their acute strokes. 11-DTB2 was measured by enzyme immunoassay in random urine samples 1 to 4 months after the stroke. Results-Eighty-seven of 92 patients enrolled were able to give a urine sample at the time of enrollment. There were 51 men and 36 women aged 36 to 87 (mean 62) years. On the basis of antithrombotic treatment before the sample collection, we divided patients into 4 groups: (1) 16 patients treated with no aspirin (no antithrombotic drugs [n=4] or ticlopidine [n=12]), (2) 21 patients treated with 81 to 325 mg aspirin per day (81 mg/d [n=2], 325 mg/d [n= 19]), (3) 20 patients treated with 650 mg aspirin per day, and (4) 30 patients treated with 975 to 1300 mg aspirin per day (975 mg/d [n=2] and 1300 mg/d [n=28]). In patients taking daily aspirin at any dose, the median urinary 11-DTB2 was 783 pg/mg creatinine compared with 1386 pg/mg creatinine in patients not taking daily aspirin (P=0.01 by Wilcoxon rank sum test). In multivariate regression analysis, aspirin use remained significantly associated with lower urinary 11-DTB2 (P=0.008). There was no dose-response effect between the 3 aspirin dose groups and urinary 11-DTB2 (P=0.70). Conclusions-In African American stroke patients, aspirin use is associated with significantly lower urinary 11-DTB2 independent of other vascular factors, and there does not appear to be a dose-response effect for aspirin doses of 325 to 1300 mg daily. The clinical significance of these finding remains to be determined.

AB - Background and Purpose-The aim of the study was to evaluate the relationship between daily aspirin use and urinary excretion of a stable thromboxane metabolite, 11-dehydrothromboxane B 2 (11-DTB2), in African American stroke patients. Methods-Subjects were a subgroup of those screened for the African American Antiplatelet Stroke Prevention Study. Subjects were within 4 months of noncardioembolic ischemic stroke and were not being treated with anticoagulants. Antithrombotic therapy at the time of urine collection varied according to the practice patterns of various attending physicians who treated the patients during their acute strokes. 11-DTB2 was measured by enzyme immunoassay in random urine samples 1 to 4 months after the stroke. Results-Eighty-seven of 92 patients enrolled were able to give a urine sample at the time of enrollment. There were 51 men and 36 women aged 36 to 87 (mean 62) years. On the basis of antithrombotic treatment before the sample collection, we divided patients into 4 groups: (1) 16 patients treated with no aspirin (no antithrombotic drugs [n=4] or ticlopidine [n=12]), (2) 21 patients treated with 81 to 325 mg aspirin per day (81 mg/d [n=2], 325 mg/d [n= 19]), (3) 20 patients treated with 650 mg aspirin per day, and (4) 30 patients treated with 975 to 1300 mg aspirin per day (975 mg/d [n=2] and 1300 mg/d [n=28]). In patients taking daily aspirin at any dose, the median urinary 11-DTB2 was 783 pg/mg creatinine compared with 1386 pg/mg creatinine in patients not taking daily aspirin (P=0.01 by Wilcoxon rank sum test). In multivariate regression analysis, aspirin use remained significantly associated with lower urinary 11-DTB2 (P=0.008). There was no dose-response effect between the 3 aspirin dose groups and urinary 11-DTB2 (P=0.70). Conclusions-In African American stroke patients, aspirin use is associated with significantly lower urinary 11-DTB2 independent of other vascular factors, and there does not appear to be a dose-response effect for aspirin doses of 325 to 1300 mg daily. The clinical significance of these finding remains to be determined.

KW - Aspirin

KW - Cerebral infarction

KW - Platelets

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0036141059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036141059&partnerID=8YFLogxK

U2 - 10.1161/hs0102.102010

DO - 10.1161/hs0102.102010

M3 - Article

VL - 33

SP - 57

EP - 60

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 1

ER -